Xeris Pharmaceuticals Inc. (XERS) shares soared 2.26% in after-hours on Wednesday, September 08, 2021, and closed the daily trading at $2.71. In the regular trading session of Wednesday, XERS’s stock lost 0.38%. XERS shares have fallen 42.76% over the last 12 months, and they have moved down 3.99% in the past week. Over the past three months, the stock has lost 33.92%, while over the past six months, it has slid down 38.94%.
Let’s have a look at its recent news and developments.
SBBP merger update with XERS
On September 08, 2021, the shareholders of Strongbridge Biopharma plc (SBBP) voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc (XERS). The business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (Xeris Biopharma Holdings or HoldCo).
XERS participation at the upcoming investor conference
Xeris Pharmaceuticals, Inc (XERS) will participate at H.C. Wainwright’s 23rd Annual Global Investment Conference which is to be held virtually on September 13-15, 2021.
Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company during the conference.
XERS update about Levothyroxine (XP-8121)
On September 01, 2021, Xeris Pharmaceuticals, Inc (XERS) completed enrollment and successfully dosed all participants in a Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety, and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism.
FDA approved XERS sNDA of Gvoke® Kit
On August 23, 2021, Xeris Pharmaceuticals, Inc. (XERS) announced that its supplemental new drug application (sNDA) of Gvoke® Kit was approved by the Food and Drug Administration (FDA) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. Gvoke Kit will be available as a 1 mg/0.2 mL single-dose vial and syringe kit. Gvoke Kit contains one (1) single-dose sterile syringe with markings for 0.1 mL (0.5 mg pediatric dose) and 0.2 mL (1 mg adult dose), and one single-dose vial containing 0.2 mL of solution.
FDA approved IND for Levothyroxine (XP-8121)
On August 11, 2021, the Food and Drug Administration (FDA) allowed XERS Investigational New Drug Application (IND) for its XeriSol levothyroxine for hypothyroidism to proceed. The active IND enables Xeris to initiate a Phase 1 clinical study for XP-8121 using its novel formulation of levothyroxine in a subcutaneous injection for the treatment of hypothyroidism. The Phase 1 study will characterize Pharmacokinetics (PK) and evaluate the safety and tolerability of XP-8121 in healthy participants.
Conclusion
The recent shareholder’s approval of the merger was the reason behind its turnaround in the after-hours on Wednesday and it can continue to perform well in the coming trading sessions.
